# A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

> **NCT06564467** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** JMT202
- **DRUG:** Placrbo

## Key facts

- **NCT ID:** NCT06564467
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-07-23
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-07-10
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06564467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06564467, "A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06564467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*